Search Results

High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light for anti-TIGIT therapies after a string of failures.

iTeos Therapeutics, Inc. announced that it has entered into a securities purchase agreement to sell 1,142,857 shares of the Company’s common stock at a price of $17.50 per share, representing a premium of approximately 44% to iTeos’ closing price on May 9, 2024 and pre-funded warrants to purchase up to 5,714,285 shares of the Common Stock at a price of $17.499 per pre-funded warrant, in a registered direct offering.

After several high-profile failures, including BMS’ $1.5B breakup with Agenus, anti-TIGIT therapies are generating cautious optimism.

iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the first quarter ended March 31, 2024 and provided a business update.

iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, announced that company management will participate in two upcoming investor conferences in March.

iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”) and its development partner GSK, have initiated the first, global Phase 3 registration study of belrestotug + dostarlimab doublet versus placebo + pembrolizumab in patients with previously untreated, unresectable, locally advanced or metastatic PD-L1 selected non-small cell lung cancer (NSCLC).

iTeos Therapeutics, Inc. announced the appointment of Jill DeSimone to its Board of Directors, effective March 7, 2024, where she will serve on the Company’s audit committee.